Synthesis of m-Prostaglandin E
Synthase-1 Inhibitor MK-7285

F. Gosselin; S. Lau; C. Nadeau; T. Trinh; P. D. O’Shea; I. W. Davies

doi:10.1055/s-0029-1219030

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Synfacts 2010(2): 0129-0129
DOI: 10.1055/s-0029-1219030

Synthesis of Natural Products and Potential Drugs

Synthesis of m-Prostaglandin E Synthase-1 Inhibitor MK-7285

Contributor(s): Philip Kocienski
F. Gosselin*, S. Lau, C. Nadeau, T. Trinh, P. D. O’Shea, I. W. Davies
Merck Frosst Center for Therapeutic Research, Kirkland, Canada and Merck Research Laboratories, Rahway, USA

Further Information

Publication History

Publication Date:
21 January 2010 (online)

Permissions and Reprints

Significance

Prostaglandin E synthase-1 converts PGH₂ into PGE₂, a key step in the propagation of inflammatory stimuli. MK-7285, a selective inhibitor of PGES-1, is a candidate for the treatment of osteoarthritis, rheumatoid arthritis, and pain.